Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | TYMS | P04818 | 7/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560266 | 1.00 | PARP1 (0.50) | PARP1TYMSTNKS2ADORA3KDM4E | |
| SCHEMBL12912283 | 0.81 | PARP1 (0.50) | PARP1TYMSTNKS2ADORA3KDM4E | |
| SCHEMBL826249 | 0.79 | TYMS (0.49) | TYMS | |
| SCHEMBL3605662 | 0.77 | KDM4E (0.49) | ADORA3KDM4ELMNAHSD17B10ALDH1A1 | |
| SCHEMBL12891201 | 0.76 | PARP1 (0.45) | PARP1TYMSTNKS2ADORA3KDM4E | |
| SCHEMBL9432425 | 0.76 | KDM4C (0.50) | PARP1TNKS2ADORA3KDM4EGLA | |
| SCHEMBL22716291 | 0.74 | PARP1 (0.45) | PARP1TYMSTNKS2ADORA3KDM4E | |
| SCHEMBL29439655 | 0.74 | PARP1 (0.45) | PARP1TYMSTNKS2ADORA3KDM4E | |
| SCHEMBL30889000 | 0.73 | ALDH1A1 (0.48) | PARP1TYMSTNKS2KDM4ELMNA | |
| SCHEMBL12909163 | 0.73 | ALDH1A1 (0.48) | PARP1TYMSTNKS2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| EP-2178562-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010529-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | claimed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | claimed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2021003157-A1 | EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2019201848-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-8618120-B2 | Synergistic combinations of VR-1 antagonists and COX-2 inhibitors | NOVARTIS AG (CH) | 2013-12-31 | — | — | US | disclosed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-7915264-B2 | Drugs for treating pain formed by arylation | NOVARTIS AG (CH) | 2011-03-29 | — | — | US | disclosed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-6420370-B1 | ANTITUMOR, ANTIBIOTIC, ANTIMALARIAL, ANTIFUNGAL OR ANTIPROTOZOAL AGENTS, OR AS SYNERGISTIC AGENTS ENZYME INHIBITORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-07-16 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
| US-6103727-A | RESISTING AND TREATING PNEUNOCYSTIS CARINII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; AUTOMIMMUNE DISEASES; AIDS; ANTICARCINOGENIC,-TUMOR,-PROTAZOA AGENTS; MALARIA; FUNGICIDES; SYNERGISTIC WITH SULFONAMIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096750-A | Furopyrimidines and methods of making and using the same derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | TRPV1, OPRL1, OPRK1 | PARP1 2409/4885TYMS 2287/4885TNKS2 2132/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | PARP1 195/4885TYMS 217/4885TNKS2 223/4885 |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | TRPV2, TRPV1, TRPV3 | PARP1 2405/4885TYMS 2931/4885TNKS2 1516/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | PARP1 507/4885TYMS 2/4885TNKS2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.